DCM
VIRX

DAFNA Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

DAFNA Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-26,314
Closed -$663K – 89
2019
Q3 		$663K Buy
+26,314
New +$759K 0.25% 66
2018
Q4 		– Sell
-10,677
Closed -$747K – 85
2018
Q3 		$747K Hold
10,677
– – 0.31% 55
2018
Q2 		$792K Hold
10,677
– – 0.37% 55
2018
Q1 		$1.02M Sell
10,677
-11,694
-52% -$2.01M 0.49% 53
2017
Q4 		$2.89M Sell
22,371
-1,381
-6% -$129K 1.56% 22
2017
Q3 		$1.61M Sell
23,752
-543
-2% -$44.3K 1% 34
2017
Q2 		$2.3M Sell
24,295
-492
-2% -$56.5K 1.64% 18
2017
Q1 		$3.56M Sell
24,787
-7,601
-23% -$1.09M 3.01% 6
2016
Q4 		$4.1M Buy
+32,388
New +$4.51M 3.61% 6
2016
Q3 		– Sell
-2,016
Closed -$232K – 95
2016
Q2 		$232K Hold
2,016
– – 0.18% 75
2016
Q1 		$229K Buy
+2,016
New +$306K 0.2% 76

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

DAFNA Capital Management's VIRX Position: Q4 2019 in Review

DAFNA Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2019, closing a stake of 26,314 shares — an estimated $663K sold.

DAFNA Capital Management first reported a position in VIRX in Q1 2016 and held it in 11 quarters. The position peaked at $4.1M in Q4 2016. 44 funds tracked by Wall St. Rank hold VIRX as of Q4 2019.

  • DAFNA Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • DAFNA Capital Management sold 26,314 Viracta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $663K.
  • DAFNA Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2016 and held it in 11 quarters.
  • DAFNA Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $4.1M in Q4 2016.
  • 44 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on DAFNA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.